Study of pegmolesatide for anemia in dialysis patients
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new medication, pegmolesatide, to treat anemia in people who have been on dialysis for at least three months. It aims to help improve red blood cell levels without needing as many other anemia treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been on hemodialysis or peritoneal dialysis for at least 3 months
- You have been taking an anemia medication (ESA) for at least 4 weeks, with a weekly dose equivalent to more than 6000 IU of short-acting EPO
- Your hemoglobin level is between 70 and less than 110 g/L
- Your iron levels (ferritin) meet certain minimums: at least 200 μg/L for hemodialysis or at least 100 μg/L for peritoneal dialysis
- You weigh at least 40 kg and have a body mass index of at least 18
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new once-monthly injection called pegmolesatide for anemia in people with kidney disease on dialysis who are already taking roxadustat. It aims to see if switching to this injection can keep hemoglobin levels stable and reduce the need for transfusions.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This trial tests a new medicine called pegmolesatide for people with chronic kidney disease and anemia. It compares switching to this new medicine versus staying on current treatments, to see if it is safe and works well.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study tests an experimental medicine for anemia in people with kidney disease who are on dialysis. It aims to see if it can help raise blood counts safely compared to standard treatments.
This trial tests whether adding romiplostim (a medication that helps increase blood cells) to standard ESA therapy can improve anemia in people on dialysis who have not responded well to ESAs alone.
Hear when a new Dialysis; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.